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Abstract
It has been hypothesized that the relatively rare autosomal dominant Alzheimer disease (ADAD) 
may be a useful model of the more frequent, sporadic, late-onset AD (LOAD). Individuals with 
ADAD have a predictable age at onset and the biomarker profile of ADAD participants in the 
preclinical stage may be used to predict disease progression and clinical onset. However, the 
extent to which the pathogenesis and neuropathology of ADAD overlaps with that of LOAD is 
equivocal. To address this uncertainty, two multicenter longitudinal observational studies, the 
Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer 
Network (DIAN), leveraged the expertise and resources of the existing Knight Alzheimer Disease 
Research Center (ADRC) at Washington University School of Medicine, St. Louis, Missouri, 
USA, to establish a Neuropathology Core (NPC). The ADNI/DIAN-NPC is systematically 
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examining the brains of all participants who come to autopsy at the 59 ADNI sites in the USA and 
Canada and the 14 DIAN sites in the USA (8), Australia (3), UK (1), and Germany (2). By 2014, 
41 ADNI and 24 DIAN autopsies (involving 9 participants and 15 family members) had been 
performed. The autopsy rate in the ADNI cohort in the most recent year was 93% (total since NPC 
inception: 70%). In summary, the ADNI/DIAN NPC has implemented a standard protocol for all 
sites to solicit permission for brain autopsy and to send brain tissue to the NPC for a standardized, 
uniform, and state-of-the-art neuropathologic assessment. The benefit to ADNI and DIAN of the 
implementation of the NPC is very clear. The NPC provides final ‘gold standard’ 
neuropathological diagnoses and data against which the antecedent observations and 
measurements of ADNI and DIAN can be compared.
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INTRODUCTION
The Alzheimer Disease Neuroimaging Initiative (ADNI) (http://www.adni-info.org/) was 
established to determine the relationships among the clinical, cognitive, imaging, genetic, 
and biochemical biomarker characteristics of sporadic, predominantly late-onset, Alzheimer 
disease (LOAD) (1,2). A complementary longitudinal observational study, the Dominantly 
Inherited Alzheimer Network (DIAN) focuses on the rarer, mainly early-onset, autosomal 
dominant AD (ADAD) (http://dian-info.org/) with known gene defects (3,4). Both ADNI 
and DIAN are informing the neuroscience of AD, identifying diagnostic, prognostic, and 
potentially theranostic biomarkers to be used in clinical trials, and helping to develop the 
most effective clinical trial protocols. Both projects are funded as public-private 
collaborations involving the National Institute of Aging of the National Institutes of Health 
(NIH) (ADNI through NIH Grant U01 AG0249049 and DIAN through U01 AG032438), 
foundations, associations, and multiple partners in industry (http://www.adni-info.org/
Scientists/ADNISponsorsAndPartners.aspx).
To achieve the goals of both ADNI and DIAN, the Neuropathology Core is essential to 
validate the clinical and biomarker classifications and diagnoses; otherwise, the data 
generated by the different clinical assessments, imaging modalities, and biomarkers obtained 
from participants believed to have AD may be contaminated by the effects of individuals 
who may not have AD or, more commonly, by the effects of common co-morbidities such as 
vascular disease and non-AD neurodegenerative disorders. A single Neuropathology Core 
site is advantageous because processing and staining methods vary across neuropathology 
laboratories, and neuropathologists may differ in their application and interpretation of 
diagnostic criteria, even for the neuropathologic diagnosis of AD. The literature has 
extensive data showing variability between different neuropathologists, sites, and countries 
(5). A single Neuropathology Core ensures uniformity and fidelity of staining and 
application of diagnostic criteria to all ADNI and DIAN participants who come to autopsy.
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The ADNI/DIAN-NPC capitalizes on the existing infrastructure of the Washington 
University Knight Alzheimer Disease Research Center (WU ADRC; P50-AG05681, JC 
Morris, PI), funded continuously by the National Institute on Aging since 1985. The 
ADRC's Administrative (Dr. Morris) and Neuropathology (Dr. Cairns) Cores provide the 
framework for both the ADNI-NPC and DIAN-NPC, and will continue to do so during the 
period of renewed funding. Fidelity of data between ADNI, DIAN and the National 
Alzheimer Coordinating Center (NACC; U01 AG016976, W. Kukull, PI) is maintained by 
using the same NACC Neuropathology Data Form. This data collection instrument is used 
by all NIH-funded Alzheimer Disease Centers (ADCs) to report neuropathological findings 
from autopsied cases and remains the primary data collection instrument. In this way, the 
ADNI/DIAN-NPC uses standard criteria for neuropathologic diagnoses of dementing illness 
and existing protocols and procedures to achieve these diagnoses (6–14). Importantly, the 
ADNI/DIAN-NPC does not interfere with or supersede neuropathologic activities at any 
ADNI or DIAN site. The ADNI/DIAN-NPC uses brain tissue obtained at the participating 
sites to provide a uniform neuropathologic assessment to support the clinical classifications 
and research aims of both ADNI and DIAN.
NIH funding of the NPC started on September 1, 2007 for ADNI, and on July 1, 2014 for 
DIAN (prior to this date, the Core received philanthropic support). The NPC serves all 
ADNI sites (n = 59) in the USA and Canada, and all DIAN sites (n = 14) in the USA (8), 
Australia (3), UK (1), and Germany (2). Now in its third phase (ADNI, ADNI GO and 
ADNI 2), ADNI 2 is studying the rate of change of cognition, function, brain structure, and 
biomarkers in 150 elderly controls, 450 participants with mild cognitive impairment, 150 
with mild to moderate AD and a new group of 100 people with significant, yet subtle, 
memory complaints, referred to as the significant memory concern cohort.
In comparison, DIAN in its initial funding period established an international registry of 
biological adult children of a parent with AD caused by an APP, PSEN1, or PSEN2 
mutation, including symptomatic and asymptomatic mutation carriers (MCs) and non-
carriers (NCs). Participants are assessed every 2 years with the uniform DIAN protocol. In 
order to accommodate the attrition of the cohort caused by recruitment to the DIAN Trials 
Unit DIAN aims to recruit to the registry 50 new participants, both MCs and NCs, in Year 1 
of the next budget period to maintain the total DIAN cohort at ~250 individuals. These new 
participants will include those who are more than 15 years younger than the estimated age at 
symptomatic onset (EAO) in order to explore the earliest observable biomarker changes of 
preclinical AD.
The ADNI/DIAN-NPC is achieving its stated goals. It has: (1) provided and implemented 
training materials and protocols to assist clinicians at ADNI and DIAN sites in obtaining 
voluntary consent for brain autopsy in participants; (2) established a central laboratory to 
provide uniform neuropathologic assessments in all autopsied participants in accordance 
with standard criteria [4–18] and has thereby promoted clinical-neuroimaging-
neuropathologic correlations; (3) established a state-of-the-art resource for fixed and frozen 
brain tissue obtained from autopsied ADNI and DIAN participants to support biomarker 
studies; (4) developed a process wherein investigators may request and receive access to the 
tissue and data for research purposes; and (5) established an ongoing interaction with the 
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Data Coordinating Centers of ADNI and DIAN to support the fidelity and exchange of NPC 
data with all ADNI and DIAN components, in support of synergistic progress toward 
common research goals.
METHODS
Provision of training materials and protocols to assist clinicians at participating sites in 
obtaining voluntary consent for brain autopsy in ADNI and DIAN participants
As there may be personnel changes over time, there is a continuing need to monitor each site 
to ensure that training and protocols for obtaining autopsies are in place, so it is essential to 
maintain a dedicated coordinator within the NPC to ensure these functions are performed 
over the period of the grant. At each site, to obtain consent for an autopsy, the physician 
leads a discussion about the autopsy with all participants (demented and non-demented) at 
their initial assessment (study partners and families are welcomed in the discussion and 
required for participants with dementia). There are three objectives of the discussion: (1) to 
convey information about the value of brain autopsy in confirming the clinical diagnosis and 
advancing knowledge regarding pre-symptomatic and symptomatic AD; (2) to initiate 
consideration of the individual's wishes concerning an autopsy; and (3) to answer questions, 
misconceptions, or concerns about autopsy. The involvement of the physician in these 
discussions emphasizes the importance of the autopsy. The discussions are repeated on an 
annual basis if the individual remains undecided about autopsy, but are terminated once a 
decision is reached. There is no pressure on an individual to decide; they are encouraged to 
involve family members, clergy, physicians, or other appropriate persons in their decision-
making. Participants are assured that a decision to decline autopsy does not in any way 
jeopardize their research participation or any other patient rights. The protocols used at each 
site are approved by the local Institutional Review Board, or Ethics Committee, and conform 
to the provisions of the Declaration of Helsinki (as revised in Brazil, 2013; http://
www.wma.net/en/30publications/10policies/b3/index.html).
When voluntary consent is granted, more detailed information is provided about procedures 
to follow at the time of death including telephone numbers to call and other guidelines 
(sample forms are available online at http://dian-info.org/ and http://www.adni-info.org/). A 
Participant is strongly encouraged to share this information with the next-of-kin, a Durable 
Power of Attorney (DPOA), and personal physician. In many states, final legal authorization 
by the Legally Authorized Representative (LAR) or next-of-kin must be obtained at the time 
of death. Each ADNI and DIAN site is encouraged to establish an autopsy coordinator 
(typically a research nurse or coordinator) who processes the autopsy consent, provides 
information as needed, and monitors the need to update any information (e.g., change of 
address) at the ADNI or DIAN participant's longitudinal assessments. The site coordinator 
also develops local procedures to facilitate autopsies outside of usual office hours (e.g., at 
evenings and weekends). The actual procedures vary in accordance with specific needs and 
resources of each site (one model used by many ADCs is to provide 24-hour telephone 
access).
At the time of death, the site autopsy coordinator (or a suitable representative) facilitates 
arrangements to ensure the completion of the autopsy. The site coordinator notifies the NPC, 
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which in turn verifies that the site neuropathologist has the dissection protocol and necessary 
materials to send the requisite tissue to the NPC in St. Louis, Missouri. The NPC, in addition 
to instructing site personnel at each ADNI and DIAN Steering Committee Meeting in these 
procedures, is available at any time to answer questions. Contact information, including a 
24-hour pager, is available. At sites that already have ADRC/ADC neuropathology services 
these continue to follow their own existing protocols. For sites that do not have established 
neuropathology services, transportation costs from the point of death to the autopsy location, 
costs of the autopsy procedure, and shipment of specimens are covered by the NPC so that 
the decedent's family and the individual site do not incur extra expense. Once the participant 
has given consent (provisional or otherwise), the Acknowledgement of Autopsy 
Authorization letter and supporting documentation are sent to the following: participant 
and/or family and/or applicable other (e.g., DPOA), nursing home, funeral home/transport 
service, and the participant's private physician (as requested).
Maintaining a central laboratory to provide uniform neuropathologic assessments
Where possible, each center is encouraged to undertake its own brain assessment and 
forward a standard set of fixed-tissue blocks or sections and frozen tissue to the NPC. Non-
standard blocks and sections (e.g. whole coronal sections) may also be handled by the NPC. 
For sites that do not routinely undertake neuropathologic studies, a separate brain removal 
protocol is available (sample protocols are available online at http://dian-info.org/ and http://
www.adni-info.org/). When requested, the Neuropathology Core makes available financial 
assistance with the autopsy, block sampling, tissue preservation, and shipping costs. The 
Neuropathology Core funds all costs in shipping frozen and fixed tissue samples to St. 
Louis, Missouri. To assist participating centers and neuropathologists with the costs of 
obtaining frozen tissue blocks and/or formalin-fixed paraffin wax-embedded tissue, costs are 
reimbursed, if requested. To minimize the burden on participating centers, formalin-fixed 
paraffin wax embedded tissue blocks, representing the following 16 areas, are taken from 
coronal slices of the left cerebrum and forwarded to the NPC: middle frontal gyrus, superior 
and middle temporal gyri, inferior parietal lobe (angular gyrus), occipital lobe (to include the 
calcarine sulcus and peristriate cortex), anterior cingulate gyrus at the level of the genu of 
the corpus callosum, posterior cingulate gyrus and precuneus at the level of the splenium, 
amygdala and entorhinal cortex, hippocampus and parahippocampal gyrus at the level of the 
lateral geniculate nucleus, striatum (caudate nucleus and putamen) at the level of the anterior 
commissure, lentiform nuclei (globus pallidus and putamen), thalamus and subthalamic 
nucleus, midbrain, pons, medulla oblongata, cerebellum with dentate nucleus, and spinal 
cord. In the unusual situation where it is impractical to forward a tissue block (e.g., if the 
entire hippocampus is used for stereology), 10 paraffin wax sections (4–8 µm) from each 
block may be sent to the NPC for systematic neuropathology and diagnosis. To provide 
tissue for biochemical studies and to advance the aims of the biomarker studies, unfixed 
brain tissue is dissected, snap frozen by contact with Teflon®-coated aluminum plates 
maintained in liquid N2 vapor in a cryogenic vessel according to the method described by 
Dr. Vonsattel and colleagues (15), and sent to the NPC. We have found that this method 
produces good quality frozen tissue with good anatomical preservation and minimal ice 
crystal artefacts (Figure 1). The following minimal number of coronal hemibrain slices (0.5 
to 1cm thick), where possible, are taken for freezing: (1) frontal lobe to include striatum; (2) 
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frontal and temporal lobe at the level of the mammillary body; (3) temporal and parietal 
lobes at the level of the lateral geniculate nucleus; and (4) occipital lobe to include the 
calcarine sulcus. In the event that a frozen hemibrain is received intact, this is coronally 
sliced at 0.5 – 1 cm intervals using an electric band saw within a fume hood in a Biohazard 
Level II laboratory – appropriate personal protective clothing is worn. All frozen slices are 
placed in Ziploc® plastic bags to prevent desiccation and stored at −80°C.
Quality of frozen brain tissue
The NPC has eleven −80°C freezers to store unfixed, frozen brain tissue. Each freezer is 
alarmed and connected to the Barnes-Jewish Hospital, St. Louis, Missouri, electronic 
equipment monitoring system which is connected to an automated paging system; the on-
duty neuropathologist and laboratory technician each carry a pager at all times in case of 
freezer failure. There is always at least one empty freezer available as back-up in the event 
of freezer failure. Routinely, the NPC preserves the left hemibrain in 10% buffered formalin, 
allowing detailed anatomical studies (e.g. language processing areas) and subsequent 
histology. Where there is evidence of a lesion, such as an infarct, in the right hemibrain, the 
coronal slice containing the lesion is preserved in formalin for histological assessment. One 
in twenty brains is received fixed whole from out-of-town sites and these permit bilateral 
sampling. To date, we have found no bilateral differences in molecular pathology but we 
continue to sample bilaterally when appropriate cases become available. The mean 
postmortem interval (PMI; mean time from death to tissue snap freezing) to date has been 
17.2 h (range: 4.5 – 38 h) for DIAN cases and 12.5 h (range: 2 – 43.1 h) for ADNI cases. 
Although the postmortem interval correlates with mRNA quality, the integrity of mRNA is 
more reliably assessed using the RNA integrity number (RIN) (16,17). The RIN for frozen 
brain is calculated using an Agilent BioAnalyzer 2100 (Agilent Technologies, Inc., Santa 
Clara, CA, USA) and is available as an additional measure of mRNA quality for cases where 
frozen tissue is available; these data are made available to investigators in addition to the 
agonal state and PMI.
Genotyping
For all cases without blood available, frozen brain samples (cerebellum) are used for DNA 
extraction and genotyping (e.g. for APOE) by the Knight ADRC Genetics Core using 
established methods (18).
Histology
In all cases, multiple histological stains (see Table 1) are performed at the NPC laboratory 
on sections cut from the blocks indicated above, and/or as requested by the neuropathologist. 
These include hematoxylin and eosin, a modified Bielschowsky silver impregnation, and 
immunohistochemistry using the following primary antibodies: phosphorylated tau (PHF1, a 
gift of Dr. Peter Davies, Albert Einstein College of Medicine, Yeshiva University, New 
York, NY); β-amyloid (10D5, Eli Lilly, Indianapolis, IN); phosphorylated α-synuclein (Cell 
Applications, San Diego, CA), and phosphorylated TDP-43 (Cosmo Bio, Carlsbad, CA). 
Additional stains and immunohistochemistry may be used when appropriate.
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Neuropathologic assessment
The operational criteria for the classification of AD and other pathologies, defined by 
NACC, are applied to all ADNI/DIAN-NPC cases [6–14]. Consensus neuropathologic 
diagnoses are determined by Dr. Cairns in collaboration with Dr. Perrin and other 
neuropathologists within the Division of Neuropathology at Washington University using 
consensus neuropathologic criteria for AD and for non-AD disorders. The NACC 
Neuropathology Form includes an entry for the diagnosis of AD by several sets of criteria: 
Khachaturian, CERAD, NIA-Reagan, and the NIA-AA [6–9]. NPC cases are thus diagnosed 
in accordance with each of these criteria as no consensus currently exists in favor of one set 
in relation to the others (particularly for the incipient stages of AD addressed by the ADNI 
and DIAN studies). This practice allows for historical comparisons with older cases that pre-
date newer diagnostic consensus criteria, and also affords investigators maximal utility in 
applying the neuropathologic diagnoses most appropriate to their research aims. The 
neuropathologic data are entered into the NACC Neuropathology Data Form and transmitted 
to the Biostatistics and Informatics Cores at the ADNI and DIAN Coordinating Centers. The 
final neuropathologic diagnosis and neuropathology report are forwarded to ADNI and 
DIAN for entry into the central database and to the center that made available the tissue.
RESULTS
The ADNI/DIAN-NPC Research Coordinator, Erin Franklin, has contacted all participating 
ADNI and DIAN sites to implement the protocols established for obtaining autopsy consent 
and performing neuropathology services. The coordinator continuously monitors the sites to 
encourage and facilitate autopsy consent in ADNI and DIAN participants. Additionally, for 
reference, all ADNI-NPC documentation is available to ADNI and DIAN site personnel at 
the Alzheimer’s Disease Cooperative Study (ADCS) website: http://www.adcs.org/
Resource/studyResources.aspx. Where autopsy procedures do not exist locally, 
arrangements have been put in place with the site PI and local hospital to collect brain tissue 
for delivery to the NPC in St Louis, Missouri. To promote the goals of the NPC and to 
inform participating sites, meetings have been held concurrently at the meetings of the 
American Association of Neuropathologists and the American Academy of Neurology.
Autopsy rate
During the period of funding of ADNI, there have been 65 participant deaths (Table 2). In 
the initial phase of ADNI (September 1st, 2005 to August 31st, 2007), when no resources 
were available for neuropathology and prior to the establishment of the NPC, there were six 
participant deaths and no autopsies (autopsy rate = 0%). The cumulative autopsy rate since 
the inception of the ADNI NPC is 70% (Table 2). Although the overall numbers to date are 
small, these data demonstrate that the Neuropathology Core has established the 
administrative organization with the participating sites to collect brains from ADNI 
participants who come to autopsy. As expected, the number of ADNI participants who come 
to autopsy is increasing as the period of the study lengthens and participants age. As of 
October 1, 2014, there were forty-one autopsies. The mean age at death was 80.7 years. 
Seventy-seven percent were male. At least one APOE ε4 allele was present in 57% of cases 
(5 cases pending). At the time of the final clinical assessment, dementia of the Alzheimer’s 
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type (DAT) was reported in all cases examined. To preserve anonymity of ADAD 
participants, demographic data from DIAN cases are not provided.
Neuropathologic assessment of ADNI and DIAN participants at autopsy
Brain samples from 41 ADNI and 24 DIAN cases (9 DIAN participants and 15 DIAN 
family members) have been received and neuropathologically assessed by the NPC (Tables 
3 and 4). Preliminary studies indicate that total Aβ load is greater (~50%) in DIAN 
participants compared with LOAD cases, similar to that observed in a previous study (19). 
Lewy body pathology (dementia with Lewy bodies and amygdala predominant Lewy 
bodies) was the most frequent comorbidity in both cohorts. Additional comorbidities 
(TDP-43 proteinopathy, argyrophilic grain disease [AGD], hippocampal sclerosis [HS], and 
infarcts) were present in the LOAD cases but these comorbidities were absent from the 
DIAN cases (Table 3). The presence of cases with an additional molecular pathology in the 
ADNI cohort is representative of other larger series, indicating that the contributions of 
vasculopathy/infarction, tauopathy, α-synucleinopathy, TDP-43 proteinopathy, and possibly 
other proteinopathies, will need to be assessed in the ADNI series as more cases come to 
autopsy. If the neuropathologic sample is representative of the total ADNI cohort of 
dementia patients, these preliminary data indicate widespread co-morbidity which may 
contribute to variance in the antemortem data obtained from different clinical and biomarker 
modalities. Likewise, if these data are also representative of the total DIAN cohort, a more 
intrinsic role for Lewy body pathology in Alzheimer disease might be considered.
Neuropathologic lesions of pre-clinical AD
The NPC has addressed the key question of what neuropathologic lesion best defines AD as 
a disease process and distinguishes it from normal aging (20–25). Even in cognitively 
normal children and young adults, evidence of neurofibrillary tangle formation may be 
present, so it is unusual to find an aged brain, even one with a clinical dementia rating 
(CDR) of 0, without some molecular pathology. Thus, neuropathological assessment of 
every case is necessary. The NPC applies four different neuropathologic diagnostic criteria 
(Khachaturian, CERAD, NIA-Reagan Institute, and the NIA-Alzheimer’s Association). The 
widely-used CERAD, NIA-Reagan, and the NIA-AA criteria emphasize lesions (neuritic 
plaques and tangles) that correlate with overt dementia. In contrast, the most recent set of 
neuropathologic criteria acknowledges the fact that established AD biomarkers (notably 
CSF Aβ42, CSF tau, and radiographic Aβ imaging with positron emission tomography 
[PET]) and neuropathology identify a preclinical stage of AD that precedes symptomatic 
AD. The new NIA-AA criteria underscore the importance of Aβ plaques as a key 
morphological lesion that best discriminates AD pathology from non-AD. We continue to 
use all four sets of criteria for each ADNI and DIAN participant who comes to autopsy, thus 
enabling other investigators to readily compare their data with the NPC data.
Multimodal studies
Both the longitudinal ADNI and DIAN studies facilitate multimodal correlations 
(neuropathology, neuroimaging, biomarkers, neuropsychology, genetics and clinical 
assessment). Toledo and Cairns and colleagues have undertaken a multimodal study of 
structural imaging (MRI), functional imaging (PET-FDG), CSF biomarkers (Aβ42, total tau, 
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phosphorylated tau, alpha-synuclein), genetics, clinical, and neuropsychological assessments 
of the first 22 ADNI autopsies (Figure 2 and [26]). Clinical diagnosis was either probable 
DAT or Alzheimer disease (AD)-type mild cognitive impairment (MCI) at last evaluation 
prior to death. All patients had a pathological diagnosis of AD, but only four had pure AD. 
A coincident pathological diagnosis of dementia with Lewy bodies (DLB), medial temporal 
lobe pathology (MTL; e.g., TDP-43 proteinopathy, argyrophilic grain disease and 
hippocampal sclerosis), or vascular pathology was present in 45.5%, 40.0% and 22.7% of 
these cases, respectively. Hallucinations were a strong predictor of coincident DLB (100% 
specificity) and a more severe dysexecutive profile was also a useful predictor of coincident 
DLB (80.0% sensitivity and 83.3% specificity). Occipital FDG-PET hypometabolism 
accurately classified coincident DLB (80% sensitivity and 100% specificity). Participants 
with coincident MTL showed lower hippocampal volume (26). This preliminary study 
indicates that biomarkers can be used to independently predict coincident AD and DLB 
pathology, a common finding in amnestic MCI and DAT patients. The DIAN cohort of 
participants (n = 7 of 9) has similar comprehensive neuropathological assessments, allowing 
neuroanatomic comparisons of histological and radiological biomarker data (Figure 3). Such 
multimodal biomarker data will help to characterize independent predictors of the different 
neuropathological substrates of cognitive impairment in these cohorts.
SUMMARY
The establishment of a centralized neuropathology laboratory (ADNI/DIAN-NPC) has 
permitted a standardized and uniform neuropathologic assessment of participants who come 
to autopsy. A central NPC provides the gold standard validation of clinical diagnoses and 
imaging and biofluid surrogates. Even with the advances in CSF and neuroimaging 
biomarkers, neuropathology is still required to determine the presence of co-morbidities 
where currently no robust biomarker exists. For example, no biomarker is currently 
available to reliably determine the presence of TDP-43 proteinopathy or AGD, and 
improved biomarkers are needed for the detection of Lewy body pathology. Retrospective 
analysis of biomarker data following neuropathological assessment may allow the 
identification of new antemortem biomarkers for these non-AD co-morbidities. The 
importance of such work is underscored by the high prevalence of Lewy body pathology in 
both LOAD and ADAD cases. The contribution of additional pathologies to the clinical, 
neuroimaging, and biomarker phenotypes will be the subject of future studies.
Previous studies indicate that a single NPC site is necessary because different 
neuropathologists use diverse processing and staining methods, as well as different 
antibodies, and interpret diagnostic criteria differently [2,3]. A single NPC ensures uniform 
staining and application of diagnostic criteria to all ADNI and DIAN participants who come 
to autopsy [2,3]. The ADNI/DIAN-NPC is built on the already established infrastructure of 
the Washington University Alzheimer Disease Research Center. The ADRC's 
Administrative (Dr. Morris) and Neuropathology (Dr. Cairns) Cores provide the framework 
for the ADNI/DIAN-NPC and continue to do so during the period of project funding. 
Compatibility of data between ADNI and DIAN and the NACC has been maintained by 
using the same NACC Neuropathology Data Form as is used by all ADCs to report 
neuropathologic findings from autopsied cases. In this way, the ADNI/DIAN-NPC uses 
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standard criteria for neuropathologic diagnoses of dementing illness and existing protocols 
and procedures to achieve these diagnoses. Importantly, the NPC does not interfere with or 
supersede neuropathologic activities at any ADNI or DIAN site, but receives brain tissue 
obtained at the participating sites to provide a uniform neuropathologic assessment.
ADNI funding of the Neuropathology Core started on September 1st, 2007. Since that time 
the NPC has become fully operational, serving all 59 ADNI sites. Funding from DIAN 
began in 2014. During the initial period of funding, the ADNI/DIAN-NPC achieved its 
stated goals. It has: (1) provided and implemented training materials and protocols to assist 
clinicians at ADNI and DIAN sites in obtaining voluntary consent for brain autopsy in 
participants; (2) established a central laboratory to provide uniform neuropathologic 
assessments in all autopsied participants in accordance with standard criteria [4–18]; (3) 
established and maintained a state-of-the-art resource for fixed and frozen brain tissue from 
autopsied participants; (4) developed a process wherein investigators may have access to the 
tissue and data for research purposes; and (5) established a workflow with the ADNI and 
DIAN Data Coordinating Centers to ensure appropriate entry of the Core's data into the 
database. Collectively, these achievements promote data sharing and collaborative research 
efforts in support of the research aims of ADNI and DIAN.
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Figure 1. 
Comparison of histology and immunohistochemistry in formalin-fixed, paraffin-embedded 
(A–C) and snap-frozen brain tissue (D–F). Mild to moderate neuronal loss and gliosis in the 
right frozen occipital lobe (D) are comparable in the left formalin-fixed occipital lobe (A) 
(hematoxylin and eosin; Brodmann area 18). Amyloid burden (Aβ plaques and cerebral 
amyloid angiopathy; Aβ(10D5) immunohistochemistry) and tauopathy (neurofibrillary 
tangles, neuropil threads and neuritic plaques; PHF1 immunohistochemistry) appear more 
severe in the frozen right occipital lobe (E and F) than in the formalin-fixed left lobe (B and 
C). Bars: A and D, 500 µm; B, C, E, F, 100 µm.
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Figure 2. 
Heatmaps summarizing the semiquantitative neuropathologic grading of the left hemibrain 
of ADNI participants. AD, Alzheimer disease; DLB, dementia with Lewy bodies. Heatmaps 
summarizing the semiquantitative neuropathological grading of molecular pathologies from 
left to right: Diffuse Plaques, diffuse Aβ plaques; Tau NFT, phospho-tau immunoreactive 
neurofibrillary tangles; Lewy Bodies, phospho-α-synuclein immunoreactive Lewy bodies; 
and TDP Dep., phospho-TDP-43-immunoreactive neuronal cytoplasmic inclusions. Adapted 
from [26].
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Figure 3. 
Semiquantitative neuropathologic heat maps facilitate PET-PiB amyloid imaging – Aβ 
plaque correlations. Upper panel: Coronal view (left) and lateral view (right) show PET-PiB 
binding in arbitrary units in a DIAN participant. Lower panel: Semiquantitative 
histopathologic data of diffuse plaques (left) and cored/compact plaques (right) from the left 
hemibrain; data are mirrored to generate a whole coronal slice at the same level as in the 
upper panel. Areas in gray not assessed.
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Table 2
ADNI autopsy rates (9-1-05 to 7-1-14)†
Funding period ADNI-
NPC
Deaths Autopsies Annual
autopsy
rate (%)
9-1-05 to 8-31-07 No 6 0 0
9-1-07 to 8-31-08 YES 7 2 28
9-1-08 to 8-31-09 YES 8 8 100
9-1-09 to 8-31-10 YES 4 1 25
9-1-10 to 8-31-11 YES 13 6 46
9-1-11 to 8-31-12 YES 3 3 100
9-1-12 to 8-31-13 YES 10 8 80
9-1-13 to 8-31-14 YES 14 13 93
Total (2005–2014) — 65 41 65
Total since NPC established — 59 41 70
†
The ADNI-NPC (Alzheimer Disease Neuroimaging Initiative Neuropathology Core) was established on September 1, 2007.
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